Plasma proteome analysis and validation of patients with community‐acquired pneumonia: A cohort study

Abstract Purpose This study aimed to investigate the diagnostic potential of plasma biomarkers of community‐acquired pneumonia (CAP) and their severity grading. Experimental design Plasma proteomes from cohort I ( n = 32) with CAP were analyzed by data‐independent acquisition mass spectrometry (MS). MetaboAnalyst 5.0 was used to statistically evaluate significant differences in proteins from different samples, and demographic and clinical data were recorded for all enrolled patients. Cohort II ( n = 80) was used to validate candidate biomarkers. Plasma protein levels were determined using quantitative enzyme‐linked immunosorbent assay (ELISA). Correlations were assessed using Pearson's correlation coefficient. A receiver operating characteristic curve was used to verify the association between the variables, CAP diagnosis, and prognosis. Results 121 differentially expressed proteins (DEPs) were obtained between CAP and controls. These DEPs were mainly aggregated in pathways of phagosome(hsa04145) and complement and coagulation cascades (hsa04610). No significant differential proteins were detected in bacterial, viral, and mixed infection groups. The plasma levels of fetuin‐A, alpha‐1‐antichymotrypsin (AACT), α1‐acid glycoprotein (A1AG), and S100A8/S100A9 heterodimers detected by ELISA were consistent with those of MS. AACT, A1AG, S100A8/S100A9 heterodimer, and fetuin‐A can potentially be used as diagnostic predictors, and fetuin‐A and AACT are potential predictors of SCAP. Conclusions and clinical relevance Plasma protein profiling can successfully identify potential biomarkers for CAP diagnosis and disease severity assessment. These biomarkers should be further studied for their clinical application.